Comparison of palliating pain with 89SrCl2 and 153Sm-EDTMP in 57 lung cancer patients

Abstract

Objects: To evaluate the effect of palliating bone pain with 89SrCl2 and 153Sm-EDTMP in 57 Lung cancer patients. Methods: All patients of metastatic bone cancer were divided into two groups: 14 patients were treated by 89SrCl2 (Group 89Sr) and 43 patients by 153Sm-EDTMP (Group 153Sm). Results: The remission rates of bone pain were 78.6% and 79.1% in Group 89Sr and Group 153Sm. There were not significantly different between Group 153Sm and Group 89Sr (P>0.05), but time of bone pain relief was much longer in Group 89Sr than Group 153Sm. 89SrCl2 therapy of disseminated skeletal matastasis in lung cancer is effective and safe. The side affects of two groups were rare. Conclusion: Good financial condition and inconvenient hospitalization patients with disseminated bone matastasis should select 89SrCl2 therapy. It may be the better of choice againts multiple bone matastasis. Show more